Abstract:Background: The pharmacokinetic/pharmacodynamics (PK/PD) target derived from the hollow-fiber system model for linezolid for treatment of the multidrug-resistant tuberculosis (MDR-TB) requires clinical validation. Therefore, this study aimed to develop a population PK model for linezolid when administered as part of a standardized treatment regimen, to identify the PK/PD threshold associated with successful treatment outcomes and to evaluate currently recommended linezolid doses.Method: This prospective multi-center cohort study of participants with laboratory-confirmed MDR-TB was conducted in five TB designated hospitals. The population PK model for linezolid was built using nonlinear mixed-effects modeling using data from 168 participants. Boosted classification and regression tree analyses (CART) were used to identify the ratio of 0- to 24-h area under the concentration-time curve (AUC0-24h) to the minimal inhibitory concentration (MIC) threshold using the BACTEC MGIT 960 method associated with successful treatment outcome and validated in multivariate analysis using data from a different and prospective cohort of 159 participants with MDR-TB. Furthermore, based on the identified thresholds, the recommended doses were evaluated by the probability of target attainment (PTA) analysis.Result: Linezolid plasma concentrations (1008 samples) from 168 subjects treated with linezolid, were best described by a 2-compartment model with first-order absorption and elimination. An AUC0–24h/MIC > 125 was identified as a threshold for successful treatment outcome. Median time to sputum culture conversion between the group with AUC0-24h/MIC above and below 125 was 2 versus 24 months; adjusted hazard ratio (aHR), 21.7; 95% confidence interval (CI), (6.4, 72.8). The boosted CART-derived threshold and its relevance to the final treatment outcome was comparable to the previously suggested target of AUC0–24h/MIC (119) using MGIT MICs in a hollow fiber infection model. Based on the threshold from the present study, at a standard linezolid dose of 600 mg daily, PTA was simulated to achieve 100% at MGIT MICs of ≤ .25 mg which included the majority (81.1%) of isolates in the study.Conclusion: We validated an AUC0–24h/MIC threshold which may serve as a target for dose adjustment to improve efficacy of linezolid in a bedaquiline-containing treatment. Linezolid exposures with the WHO-recommended dose (600 mg daily) was sufficient for all the M. tb isolates with MIC ≤ .25 mg/L.

Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers

LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring.

Model Based Identification of Linezolid Exposure–toxicity Thresholds in Hospitalized Patients

Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics

Therapeutic Drug Monitoring and Receiver Operating Characteristic Curve Prediction May Reduce the Development of Linezolid-Associated Thrombocytopenia in Critically Ill Patients

Therapeutic Drug Monitoring of Linezolid and Exploring Optimal Regimens and a Toxicity-Related Nomogram in Elderly Patients: a Multicentre, Prospective, Non-Interventional Study.

Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation

Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis

Therapeutic drug management of linezolid: a missed opportunity for clinicians?

Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients

Population Pharmacokinetics and Dose Evaluations of Linezolid in the Treatment of Multidrug-Resistant Tuberculosis

High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid

Dose Optimization of Linezolid in Critically Ill Patients Based on A Population Pharmacokinetics Model: A Two-center Prospective Interventional Study

Development and Validation of a Risk Prediction Model of Linezolid-induced Thrombocytopenia in Elderly Patients

Retrospective Study of Adverse Drug Reaction(ADR) Induced by Linezolid in Hematological System

Analysis of the Effect Factors of Thrombocytopenia Associated with Linezolid

Determinants of beta-lactam PK/PD target attainment in critically ill patients: A single center retrospective study

Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia

Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients

Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis

Developments in the Pharmacokinetic/pharmacodynamic Index of Linezolid: a Step Toward Dose Optimization Using Monte Carlo Simulation in Critically Ill Patients.